ARTICLES BY JERRY CHAPMAN
-
![iStock-489749225]( "How Do FDA, MHRA, & Russia's Drug Inspectorate Evaluate & Escalate Inspection Findings?")
How Do FDA, MHRA, & Russia's Drug Inspectorate Evaluate & Escalate Inspection Findings?10/21/2020Representatives from the Russian Federation State Institute of Drugs and Good Practices, the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA), and the U.S. FDA share their processes for evaluating and escalating inspection findings to determine if regulatory action is needed.
-
![Number 10]( "Comparing The Top 10 Pharma Inspection Findings From FDA, MHRA, & Russia's Drug Inspectorate")
Comparing The Top 10 Pharma Inspection Findings From FDA, MHRA, & Russia's Drug Inspectorate10/7/2020Representatives from the Russian Federation Ministry of Health, the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA), and the U.S. FDA share their top 10 pharma company inspection findings from FY2019, revealing many similarities and a few differences.
-
![Quality Assurance Concept]( "Life Science Chief Quality Officers Are Redesigning Quality For The 21st Century")
Life Science Chief Quality Officers Are Redesigning Quality For The 21st Century3/27/2019With input from FDA and regulators, CQOs are pursuing means to analyze huge data sets, manage complex manufacturing systems, and operate smoothly between varied products, languages, and cultures.
Jerry Chapman
Jerry is Govzilla’s senior GMP quality expert. He brings 40 years’ experience in the pharma industry, including 31 years at Eli Lilly, where he worked in product development, biosynthetic human insulin manufacturing, and site and corporate quality roles. In corporate quality, he designed and implemented a comprehensive GMP Intelligence process to identify, analyze, and archive pertinent drug GMP regulations, inspection findings, trends, and best practices in the U.S. and internationally. Chapman was founder and chairman of the GMP Intelligence subgroup of the Midwest Discussion Group from 2005 to 2010. He also served as senior editor at International Pharmaceutical Quality for six years; has been an invited speaker at PDA, AAPS, ISPE, and RAPS events; and was a consultant for the animal health and compounding pharmacy industries.